EIN Presswire: Brain Cancer Featured Press Releases

Amarantus BioSciences Licenses Disease Diagnostic Biomarker Test from Power3 Medical Products

Mon, 23 Jan 2012 09:16:17 +0000

Amarantus BioSciences Licenses Parkinson's Disease Diagnostic Biomarker Test from Power3 Medical Products

/EINPresswire.com/ SUNNYVALE, CA and THE WOODLANDS, TX - January 23, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. (OTCBB: PWRM) for the NuroPro(R) Blood Test as it relates to Parkinson's disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.

The NuroPro Blood Test is Power3's diagnostic platform for the early detection of neurodegenerative diseases. It is being developed as a tool to assist physicians to more accurately diagnose disease and monitor progression. The platform involves monitoring the concentration of 57 protein markers in blood serum identified to be linked to neurodegeneration in order to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Amarantus' license is focused on the further development of a subset of 21 of these protein markers specifically targeting early diagnosis and ongoing monitoring of Parkinson's disease.
The Parkinson's disease application of the NuroPro Blood Test has completed proof-of-concept and Phase 1 clinical validation studies. Amarantus plans to initiate a Phase 2 clinical validation study in the first half of 2012 that is expected to last approximately six months. Management of the trial will be partnered to Power3 as part of its ongoing strategy to build its Clinical Research Organization business unit.

"The in-license of the NuroPro Blood Test for Parkinson's disease expands our product offering as we strive to become the leader in the evaluation and treatment of Parkinson's disease," said Gerald Commissioning, President and CEO of Amarantus BioSciences. "Now that we will be able to tailor our therapeutic development pathway towards a companion diagnostic product that we control, Amarantus is positioned to build a strategic advantage over competitors as the execution of our clinical and regulatory strategy continues to advance MANF as a disease-modifying treatment for Parkinson's disease. The Company was also recently awarded the composition of matter patent for MANF by the US Patent & Trademark Office, further enhancing our position in the field."
Given the length of time it takes to accurately diagnose Parkinson's disease and the relatively high early misdiagnosis rates, the development of a blood-based biomarker test is likely to generate significant interest among neurologists and primary care physicians as it will allow them to intervene at an earlier stage in disease progression. In addition, the NuroPro Blood test for Parkinson's may generate partnering and revenue opportunities for Amarantus.
The terms of the agreement give Amarantus an exclusive license to develop, manufacture, have manufactured, use, market, sell and import medical devices and methods under the Power3 Parkinson's Disease Intellectual Property (IP). In addition, the license provides Amarantus an exclusive, royalty-free, fully paid-up worldwide license to Power3 know-how, patents and patent applications which relate to medical devices and methods for the treatment of neurodegenerative disease as it relates to Parkinson's disease.

Amarantus paid a $25,000 exclusivity fee in common stock on November 11, 2011 and will issue to Power3 $475,000 worth of common stock. In addition, Amarantus has an option to purchase all of the Parkinson's Disease IP owned by Power3 for $500,000 worth of common stock and maintains a Right of First Refusal to acquire the balance of the NuroPro platform for Alzheimer's, ALS and all other neurodegenerative diseases. The initial term of this License Agreement is for one year and is renewable upon mutual written agreement of the parties.

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (OTCBB:PWRM) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and Parkinson's disease.

MEDIA CONTACTS:

Lou Levenstein
info@seraphimstrategies.com
727.489.9939

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

Study comparisons of exacerbations of Asthma & COPD

Tue, 10 Jan 2012 20:27:29 +0000

SMI is proud to present the 8th annual conference…
Asthma & COPD
Monday 16th & Tuesday 17th April 2012, Copthorne Tara Hotel, London

/EINPresswire.com/ SMi present their 8th annual Asthma & COPD event to be held in London on Monday 16th & Tuesday 17th of Apil 2012. Building on the success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, this year will see an elite panel of speakers drawn for both industry and academia.

The successful combination of academic KOLs and leading senior big Pharma speakers offers an ideal and comprehensive platform for the study of both Asthma & COPD.

The similarities between the two conditions are juxtoposed with the subtle and important differences. Both pose unique and complex challenges, and these differences must be identified and isolated. As respiratory research continues to grow and prosper this event contributes further towards the understanding of how they can be dealt with in a successful and cost effective manner.

This event offers an ideal platform for those who have recently moved in to respiratory studies as well as established professionals. This is an opportunity to network with the leading protagonists in the field and to learn from their knowledge and experience as well as to share your own.

Key Speakers Include:

•Professor Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine
•Professor Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine
•Professor Wisia Wedzicha, Professor Respiratory Medicine, University College London
•Stefano Petruzzelli, Head, Respiratory Medicine Unit Corporate Clinical Development, Chiesi Farmaceutici
•Thys van der Molen, Professor of Primary Care Respiratory Medicine, University of Groningen University Medical Centre Groningen Centre for Medical Biomics
•Louise Donnelly, Reader in Respiratory Cell Biology, National Heart & Lung Institute

>>> To view the full programme and speakers visit our website http://www.smi-online.co.uk/cancer-imaging38.asp
For more details contact Ninica Hussain on: +44 (0) 20 7827 6115
e-mail: nhussain@smi-online.co.uk

Steve Sommer, M.D., Ph.D., Founder, OncoMOTOR to Present Investor Opportunities at OneMedForum 2012

Mon, 09 Jan 2012 16:47:42 +0000

OncoMOTOR is a new company focused on developing highly sensitive diagnostic tests that can be used in either the doctor's office or hospital to enable the very early diagnosis of cancer.

/EINPresswire.com/San Francisco, CA - Dr. Steve Sommer will discuss investment opportunities with OncoMOTOR at OneMedForum 2012 on Wed., January 11th at 11:40 a.m., held at the Sir Francis Drake Hotel, San Francisco.

"The Company has harnessed the ability to track the effects of therapy on cancer patients, and utilizes NextGen sequencing to identify a "signature" of somatic mutations within a cancer," says Dr. Sommer. The enabling technology, invented by Dr. Sommer and licensed by OncoMOTOR, is Pyrophosphorolysis Activated Polymerization (PAP) which can often detect mutations at one part in a million or better. Personalized PAP assays can be developed to detect cancer signatures in plasma, the cellular component of blood, or another accessible tissue, and these signatures can reveal cancers anywhere in the body at sizes below the detection threshold of state of the art imaging methods, according to Dr. Sommer.

PAP assays custom designed for the cancer patient can be used for Monitoring Of Therapy Or Recurrence (MOTOR), a tool in cancer treatment.

"For detection of new cancers, a standard suite of PAP assays can be developed as an annual routine screen for cancer, a screening test which could detect most cancers at a very early and curable stage," says Dr. Sommer. "About 7000 cancer mutations should provide a signature in for 90% of tumors in the body. The combination of PAP, NextGen sequencing, and interpretation make for a powerful combination for this earlier-stage diagnostic-biotechnology company. These powerful tests can detect and quantitate any cancer type at levels generally below imaging tests....and also find new unknown cancers where most are cured by just surgery, even for common cancers now generally lethal within a year, such as lung cancer and pancreatic cancer."

OncoMOTOR is a molecular diagnostic laboratory founded in 2011 by Steve S. Sommer, MD, PhD. The core technology is Pyrophosphorolysis Activated Polymerization (PAP).

For more information call 626.804.3645

About Steve Sommer, M.D., Ph.D.
Dr. Steve Sommer, Founder and Chief Scientific Officer of OncoMOTOR is a Founding Fellow of the American College of Medical Genetics with 25 years experience in Clinical Molecular Diagnosis and over 300 scientific publications and patents. About 150 papers are on mutagenesis and cancer.

Dr. Sommer is a professor of genetics and founding member of the American College of Medical Genetics. Research and clinical preventive genetics have been the underlying focus of his research for two decades. He has more than 300 scientific publications. He has developed more than 30 methods and reagents and holds multiple patents. Dr. Sommer's honors include: election to the prestigious American Society of Clinical Investigation (ASCI) and the American Association of Physicians (AAP).

Dr. Sommer was Medical Staff Fellow at the National Institutes of Health, performing research in yeast molecular genetics and receiving residency training in Pathology and fellowship training in Clinical Genetics. He is a Founding Fellow of the American College of Medical Genetics in Clinical Genetics and in Clinical Molecular Genetics. As Assistant Professor in the Department of Biochemistry at the Mayo Clinic, he developed a suite of early PCR-based methods including GAWTS (Genomic Amplification with Transcript Sequencing), the first workable PCR-based method for performing direct human genomic sequencing, and co-developed allele-specific amplification. He applied those methods to i) the analysis of spontaneous human mutagenesis and its relation to cancer and genetic disease and ii) search for genes & predisposing to neuropsychiatric disease, especially schizophrenia and autism as these divergent biological questions were both limited by the ability to retrieve appropriate information from nucleic acids.

He moved to City of Hope in 1996, were he became Chair of the research Department of Molecular Genetics and the clinical Department of Molecular Diagnosis. From 1997 to 2006, he led the Clinical Molecular Diagnostic Laboratory (CMDL), which became one of the largest academic DNA diagnostic reference laboratories in the U.S. Dr. Sommer received his Ph.D. in Molecular Biology from Rockefeller University and his M.D. from Cornell Medical School.
#####

Gary Grasso, Director
Doctor's P.R. & Medical News
626 222-7955
http://www.doctorspr.com

PR Courtesy of Online PR Media: http://bit.ly/zhB3px

Revolutionary Healthcare Concept Fills Critical Niche

Fri, 15 Jul 2011 00:29:07 +0000

What about the other 23 hours?

/EINPresswire.com/ Wilmington DE: Advances in awareness, early detection, prevention and the treatment of cancer mean cancer survival rates are increasing according to National Cancer Institute Cancer Trends Progress Report . However, nationally, we continue to fall short of the Dept HHS Healthy People 2010 targets. The role of formal and informal support groups as a vehicle to improve patient outcomes as part of the total treatment experience are well documented and generally acknowledged by health care professionals. Despite these findings fewer than half of diagnosed patients in some studies were given information about support groups.
Combining the efficacy of support groups and the explosive popularity of social networking a revolutionary new company has emerged to fill a critical niche in the treatment of chronic disease. Team Health Inc.is pleased to announce the launch of www.OurHomeGame.com, a 24/7, on-demand, video driven, high touch health coaching platform. Ourhomegame.com supports and delivers research based education and information that enhances patient compliance and manages patient expectations. This, in turn, actually strengthens the collaborative relationship between primary care physician, specialist, complimentary care, patient, family and community support. And does so in a way that is engaging, interactive and personalized.

Founder of Our Home Game.com Steve White, states "It is not unusual to feel that you are the only person who has experienced the pain you are feeling, particularly if you are going through the transition of emotional and physical changes caused by the onset of symptoms. Above all, it is our opinion that the most important thing patients with a serious or life threatening disease can have is support." Our Home Game is a company dedicated to the healthy and meaningful adaptation to living with a debilitating disease. The company currently addresses a niche in the market place that has been previously left to the individual who had been diagnosed with the disease.

Many times it's the uncertainty that patients have that can make things worse than they need to be. Unfortunately, there generally is not a comprehensive guidebook provided to patients who are diagnosed. The Physician generally gives the patient the bad news and perhaps a pamphlet with an apology, then refers them to a different doctor. "People need compassion, connection and understanding. Patients need certainty and direction. Our Home Game was designed to assist these patients in designing a life outside the doctor's visits. If a patient sees his or her doctor an hour a day, our question is-what are they doing with the other 23 hours? The company provides 24/7 support and coaching for those in need. A big part of the battle is expectations. Patients can demonstrate tremendous resilience when they understand what to expect." Continues White. For further information, visit www.ourhomegame.com

Press Contact:
Troy Bohlke
10 Day Publicity
480-584-2909
www.10daypublicity.com

Brain Cancer and Cell Phones - A Personal Account of a Psychologist's Battle with Glioblastoma

Wed, 15 Jun 2011 17:25:09 +0000

/EINPresswire.com/ Herman Lowe, who has been battling brain cancer for over two years, has written a free online book about his journey and what he has done to try to help others with this deadly disease. Lowe, a semi-retired clinical psychologist, explains in the book why he is convinced that the use of cell phones has played a significant role in his contracting brain cancer.

Herman Lowe, who has been battling terminal brain cancer, Glioblastoma, for over two years, has written a free online book, "Brain Cancer: Beating the Odds" about his journey and what he has done to try to help others with this deadly disease. Lowe, a semi-retired clinical psychologist, explains in the book why he is convinced that the use of cell phones has played a significant role in his contracting brain cancer. While he knows that scientific evidence for the link between cell phones and cancer has not reached a level of certainty, he felt vindicated when the World Health Organization (WHO) issued a recent warning about the potential link between them.

While the scientists continue to explore whether cell phones cause cancer, Lowe preaches that it is "better to be safe than sorry." After his diagnosis with brain cancer, he set about reducing his own exposure to cell phone radiation by simply stopping using one, and encouraging others to use them more responsibly. His wife, Mercia Tapping, CEO/President of AllergyBuyersClub.com, also thought that she could provide for her husband with a healthy home environment which just might prolong his life. On June 2nd, 2011 the couple celebrated that Lowe had survived 2 years since his diagnosis, which puts him in the 20% of patients for survival rate. Only 5% reach the 3 year mark. As Lowe puts it, "I felt I had to help myself beyond the excellent conventional treatment I have been receiving at Dana Farber Hospital in Boston."

Lowe knows that no one can fully understand why so far he has been lucky enough to beat the odds. But he felt he should write a book about his journey, and what he has done to prolong his life, just in case someone wants to follow in his footsteps.

His online book is available online in downloadable format at http://www.allergybuyersclub.com/press/brain-cancer-and-cell-phones.html. Lowe hopes that those people who read his book will make a donation to Dana Farber where a Herman Lowe Fund has been set up in his name.

Herman Lowe and his wife, Mercia Tapping, can be contacted through her web site, AllergyBuyersClub.com, via the "Contact Us" form and then "Contact our CEO" option.

Media Contact:
Gary McEldowney
Boston Green Goods, Inc.
781-419-5500
http://www.AllergyBuyersClub.com

PR courtesy of Online PR Media: http://bit.ly/mdb2QQ

Release: Florida's Nurse Anesthetists Launch Education Campaign

Wed, 26 Jan 2011 09:29:03 +0000

For Immediate Release
Tuesday, January 25, 2011

Contact: Sarah Bascom
(850) 294-6636
or Christian Ulvert
(850) 559-2778

Florida's Nurse Anesthetists Launch Education Campaign
Florida Association of Nurse Anesthetists should be part of the overall solution to Florida's health care challenges

Altamonte Springs, Fla. - The Florida Association of Nurse Anesthetists (FANA) today launched an education campaign as part of National Nurse Anesthetist Week to celebrate and recognize the important contributions made by Certified Registered Nurse Anesthetists (CRNAs) to Florida's health care system.

"Medicaid reform and containing the ever increasing cost of health care will be a main topic during the upcoming legislative session and we believe that FANA and CRNAs should be a part of that conversation and part of the overall solution," said Michael Steighner, ARNP, CRNA and president of FANA. "We are launching an education and awareness effort, in concert with National Nurse Anesthetist Week to drive discussion among legislators and key stakeholders on how CRNAs can bring positive change to Florida's health care system. CRNAs deliver safe, accessible and high quality care to Florida's patients and we look forward to discussing how we can help in the coming months of the legislative session."

As the main hands-on providers of anesthesia care in civilian and military settings, CRNAs administer comprehensive anesthesia care to patients before, during and after surgical and obstetrical procedures and are the primary anesthesia professionals in rural and medically underserved areas. CRNAs practice in every setting in which anesthesia is administered, including traditional hospital surgical and obstetrical suites, interventional pain management, critical access hospitals and ambulatory surgical centers.

"CRNAs can help bring needed reforms and cost-savings to our health care system and FANA is prepared to offer safe, sensible and cost effective solutions, we just need a seat at the table," added President Steighner.

National Nurse Anesthetist Week was established by the American Association of Nurse Anesthetists (AANA) was created to educate the public about anesthesia safety and the benefits of receiving anesthesia care from a nurse anesthetist.

Founded in 1936, the Florida Association of Nurse Anesthetists (FANA) represents 3,500 Certified Registered Nurse Anesthetists (CRNAs) licensed in Florida. FANA advocates for its patients and members in legislative and governmental affairs and serves as a resource for CRNAs, the nursing and medical professions, hospitals, health care facilities and others interested in anesthesia care. For more information on FANA, please visit www.fana.org.

###

AbrahamSohn Group Makes Generous Donation to Cancer Charity

Tue, 16 Nov 2010 08:20:41 +0000

Simon Patterson presented Kowloon-based charity Cancer Options

For Immediate Release

Hong Kong--November 16, 2010--Recently at a festive fundraiser party and silent auction at the Emperor's Ballroom in Hong Kong, AbrahamSohn co-founder and Executive Vice President Simon Patterson presented Kowloon-based charity Cancer Options with a donation check of one hundred and fifteen thousand dollars ($115,000).

"We are thrilled to be able to make this donation," stated Simon as he presented the check to Cancer Options Executive Director Sarah Lee Wang. "Your organization was right there with me when I was going through my treatment and you have helped so many others in amazing ways." Simon, a cancer survivor himself, recalled how representatives from the organization were by his side during his treatment battle. It was a heartwarming moment to see Sarah's reaction when the check was presented. "They had no idea of the amount," he said. "It was my time to give back."

The Kowloon-based charity educates patients on treatment options, advocates informed patient choice, and promotes public awareness regarding cancer risk reduction. They offer emotional, physical, and even monetary support, to people diagnosed with cancer.

Contact:

Kelly Chan
Press Agent
AbrahamSohn Group
1 Austin Road West
Hong Kong
8-523-019-9419
contact@abrahamsohn-group.com
http://www.abrahamsohn-group.com

PR provided by Press Release Distribution, a division of Drummond Post Media.

###

Book Tries to Revive Debate about Cell Phones and Brain Cancer

Mon, 15 Nov 2010 15:30:16 +0000

Nov. 15, 2010 /EIN Presswire/ - Devra Davis, an epidemiologist at the University of Pittsburgh, argues in her book "Disconnect" that cell phone radiation may be linked to an increase in brain cancer among the 20 to 29 age group. Mostly, she argues that the debate as to whether cell phones could cause cancer is unsettled.

Worries over low-level radiation emitted by cell phones are widely dismissed by the mobile phone industry and many researchers, but Davis asserts that low-energy radiation could damage cells in a way that could cause cancer, such as in studies where rats exposed to such radiation over a long period of time had damaged brain DNA.

The Interphone International Case-Control Study, the largest study of cell phone use and brain cancer, found no correlation. However, the Federal Communications Commission recommends that people, especially children and pregnant women, limit their cell phone radiation exposure when possible.

For more brain cancer news, visit Brain Cancer News Today, a brain cancer media monitoring service from EIN News.

October 17-24, 2010 is Radon Awareness Week. Radon Mitigator Jamey Gelina Urges Families to Test

Wed, 13 Oct 2010 12:18:28 +0000

/EINPresswire.com/ Radon gas is the second leading cause of lung cancer reports the Centers for Disease Control. Health agencies throughout the United States are urging Americans to test their homes for this deadly gas during National Radon Awareness Week. This year, the week of October 17-24 has been designated as the week to take action against radon.

About a year ago, The World Health Organization announced a new action level of 2.7 pCi/l for indoor radon. This is a 32% reduction from the previously accepted limit of 4.0. This new guideline was prompted by a recent compilation of studies submitted by scientists throughout the World which conclusively point to radon as the second leading cause of lung cancer next to smoking. Based on the new 2.7 threshold, millions of homes will require radon remediation work to reduce radon levels.

Each year, hundreds of thousands of deaths throughout the World are caused by exposure to radon. This new plan of action by the World Health Organization will save millions of lives by prompting homeowners toward radon reduction. More than 100 scientists from 30 countries participated in the World Health Organization International Radon Project and assisted in the publishing of the Handbook on Indoor Radon which was released earlier this month. The book is a useful resource for concerned homeowners or anyone who wants to learn more about the toxic carcinogen known as radon. It outlines the years of research and the very conclusive findings that have triggered a push for stricter legislation and construction practices that will reduce the risk of lung cancer from indoor radon exposure.

"All homes should be tested for radon regardless of the geographic location or type of construction. Since radon gas cannot be detected by human senses, the only way to know if a home has a radon problem is to conduct the test," according to Jamey Gelina, President of Air Quality Control Agency; one of North America's leading radon mitigation companies. His Agency has fixed radon problems in over 20,000 buildings and houses. "We have performed mitigation work for countless families who have been victims of radon-induced lung cancer which could have been prevented if they had been advised of radon testing before they purchased their homes," Mr. Gelina added. Jamey has worked with homeowners across the country to help them reduce their exposure to radon including Colorado, Wisconsin, Minnesota, Michigan, Indiana, Kentucky, Pennsylvania, Maryland, New York, Connecticut, and Massachusetts. "Radon problems are not isolated to these areas. Elevated radon levels have been found in every state in the U.S." Gelina added.

The good news is that radon testing is easy and inexpensive. When elevated levels are detected, there are proven remediation methods that can reduce the radon to acceptable levels. Take advantage of Radon Awareness Week (October 17th - October 24th, 2010) as an opportunity to get your home tested for this silent killer. The health of your family could be at risk, and the only way to know is to test. Learn more about radon gas, the health effects associated with exposure, and how to reduce the levels within your home at http://RadonWeek.WordPress.com/

Natural Living Helps Cancer Patients with Natural Medicine, Herbal Formulas and Organic Food

Wed, 24 Mar 2010 14:49:47 +0000

In a new seven minute video produced by natural living expert Larry Cook, Dr. Simon Barker, ND - a California Licensed Naturopathic Doctor - explains how he uses the principles of natural living to help patients with cancer.

In a new seven minute video produced by natural living expert Larry Cook, Dr. Simon Barker, ND - a California Licensed Naturopathic Doctor - shares how he uses the principles of natural living - such as eating whole organic food, prescribing herbal formulas and using natural medicine - to successfully help patients with cancer.

In simple terms, cancer occurs when certain cells in the body behave erratically and independently without regard for the rest of the body. The cells replicate, usually growing into a mass. As the cancer grows, it can spread throughout the body and, if left unchecked, can eventually kill the person.

Dr. Barker says, "Patients who come to see me have usually already been diagnosed with cancer and are either in the midst of doing conventional treatment or are in remission. This means I'll be interested in helping them minimize the side-effects of their treatment, or in helping them get to the root cause of what caused the cancer in the first place so that it won't come back. I'll run a number of lab tests to check how their body is functioning and then prescribe an appropriate treatment."

"My first treatment goal is to help the immune system function properly again, and I usually start with dietary changes, such as eliminating sugar-based foods and processed foods, and incorporating whole organic foods." "I'll use specific nutritional supplements such as Vitamins A or D, herbs such as mistletoe, supplements such fish oil, as well as other natural remedies designed to help the body reverse the root causes of cancer. I've been working with cancer patients for over a decade, and when my patients follow my natural medicine protocol, I have a very good success rate," says Barker.

Naturopathic Medicine is a natural medicine model that emphasizes the identification and treatment of the root cause of the disease or health condition in order to restore health. Conventional and alternative diagnostic testing is used to evaluate the root cause of disease symptoms and then diet and lifestyle modifications are prescribed along with appropriate nutrients, botanical medicine, homeopathic remedies and other natural therapies to enable healing of the affected areas of the body.

Mr. Cook says, "Natural living works because the body will heal itself when given the right conditions. When people take full responsibility for their food choices and lifestyle choices that affect overall health and also decide to work with a qualified natural medicine professional such as a Naturopathic Doctor, cancer can be prevented from returning." To watch the video of Dr. Barker explain how he successfully helps patients who have cancer, visit http://www.thenaturalguide.com/nd/sb-cancer.html. To learn more about natural living, visit http://www.thenaturalguide.com.

Press Release courtesy of Online PR News: (http://www.onlineprnews.com).

For More Information:
http://www.youtube.com/watch?v=iSodczAej_Q
http://www.thenaturalguide.com/organic-food.htm
http://www.thenaturalguide.com/natural-medicine.htm

Media Contact
Larry Cook, Author
The Beginner's Guide to Natural Living
larry@thenaturalguide.com
213-422-2066

Good Morning, Americans, Today You Have A Right To Health Care

Mon, 22 Mar 2010 13:17:33 +0000

March 22, 2010

By Joe Rothstein
Editor, EINNEWS.COM

Good morning, Americans. Today you have a right to health care.

Just as you have long had a right to a lawyer, and to education you have a right to health care. You have a right to health care, just as those living in every other developed country have long had.

In the scheme of things, what Congress finally enacted Sunday night is not very original or revolutionary. Health insurance remains a private, for-profit business. But the effort to enact even this degree of fundamental change has been one of the most longstanding political battles in U.S. history. And the way it was framed over the past 12 months you might have thought to do even this much would bring apocalyptic destruction to the U.S.

In fact, Republican House Leader John Boehner used that very word, "apocalypse," to describe what he envisioned the result for the U.S. He said it during a Sunday morning TV talk show and again last night during the debate. So he must believe it.

I watched the spectacle of the final debate from the House press gallery most of yesterday afternoon and long into the night. Being there provided impressions not available from TV: The tension on Democrats' faces as they watched with deepening concern their vote count stall in the low 200s with just a few minutes left to go. Could Speaker Nancy Pelosi have brought this mother-of-all political wars to the floor with too few votes to pass?

And then, within seconds, the electronic vote board ran up from 202 "yes" votes to 215. Democrats' realization that they were on the brink of passage spread like sheet lightning across the House floor.

"One more vote," "one more vote," they chanted. And finally----that one more vote lit up to insure passage, followed by three more to provide a comfort zone.

The moments leading up to the vote triggered a rowdy, slap happy, boos and cheers festival. It was much like two heavyweights who'd taken a lot of punches in a grueling marathon battle finally cutting loose before the final bell, with blood-lust crowds cheering them on.

The leaders of both sides were hailed as heroes in their final speeches: Boehner and his deputy Eric Cantor in opposition, Pelosi for the majority. Pelosi entered from the rear of the chamber, down the long aisle to the speaker's well, to rock-star treatment by cheering Democrats. This was an entrance and treatment usually reserved for presidents and State of the Union addresses.

It's popular to say that President Obama and the Democrats are "all in" on health care reform. There's no denying that---the party has a lot of chips on this table. Everyone on the House floor last night knew it. But the other side of that card is true, too. The Republicans also are "all in." For its failure.

What if by November the streets are clear of health care protesters, Rush Limbaugh and Glenn Beck have moved on to declaring immigration reform the trigger that will blow up the republic, and tens of millions of Americans are wondering, if they think about it at all, what the health care fuss was all about. For most of those now lucky enough to have good health insurance at reasonable rates nothing will have changed. For many others, the impact will be immediate and positive.

In that pre-election environment won't John Boehner's warnings about an "apocalypse" sound a bit loony? Won't the uniformity of the Republican vote against health reform seem more political than responsible?

Common wisdom has it that the battle for health reform had its modern day antecedent during Harry Truman's presidency. But a dozen years before Truman asked Congress to enact health reform, the issue was a very hot topic for Franklin Roosevelt. FDR was being pushed hard to incorporate health reform in the new Social Security program he was proposing. But in the end FDR became convinced that the only way he could squeeze Social Security through Congress was to abandon health reform. And he did.

A historical note that might apply in 2010: After Social Security was enacted in 1936 Democrats added 12 more Democrats to their already big majority in the House and 6 to the Senate.

During the vote and final debate, Rep. John Dingell of Michigan sat in one of the front row seats. He had labored in on crutches, with what appeared to be painful effort. Dingell's the longest serving member of Congress---55 years, the third longest serving member in the history of the U.S. After passage, Dingell was mobbed by well-wishers. For 53 of Dingell's 55 years in Congress he has introduced health reform legislation. He lived to see it finally happen.

Once the final tally was announced the Democrats broke into another spontaneous chant, "Yes, We Can." "Yes, We Can." You might have thought they'd emerged from March Madness winning the Final Four.

In her final speech, Speaker Pelosi proposed a corollary to Tip O'Neill's famous dictum, "All politics is local." Pelosi's formulation: "All politics is personal."

She meant that the health benefits embedded in the bill would affect all Americans personally. But she could just as well have meant that the politics of getting the bill passed was taken very personally by all House members, Democrats and Republicans alike. The Democrats believe they have accomplished a change as positive and historic as Social Security and Medicare. The Republicans believe, as Boehner said, that the bill will create an "apocalypse."

Whether all of this drives an even bigger wedge between members of the two parties on all of the other major issues in the queue waiting for attention is a question for another day. As will voters' judgment about whether the politics of health care justified shoving all their chips on this table.

Sample Healthcare Industry Today for Free

Thu, 18 Feb 2010 08:56:59 +0000

Sample Healthcare Industry Today for Free

February 18, 2010 /EIN PRESSWIRE/ Until Feb. 22, visitors to Healthcare Industry Today can access all the news and information on healthcare companies, heathcare reform, pharmaceuticals, medical research, policy issues and more at no charge and with no obligation.

To gain free access to Healthcare Industry Today, go to http://health.einnews.com/login.php and enter the following login information:

Login: free
Password: access

With this login/password, you gain full membership access to Healthcare Industry Today, a service of EIN News, an industry leader in news monitoring for researchers and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest health news from around the world, saving them valuable time they'd spend searching for information.

If you're a healthcare industry professional, an analyst, an activist, an educator, or simply someone interested in the healthcare industry, don't miss your chance to sample the EIN News service and stay abreast of the most up-to-date news and information on the web.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.

Breast Cancer Treatment in Large, Fewer Doses of Radiotherapy Lessens Side Effects

Mon, 08 Feb 2010 15:03:33 +0000

February 8, 2010 /EIN PRESSWIRE/ The Institute of Cancer Research has found that women with breast cancer had more manageable side effects when their radiotherapy was delivered in larger - but fewer - doses.

The study found that women who received the larger doses experienced less skin changes than those subjected to the normal dose. These larger, less-frequent doses also reduce the total amount of radiation delivered over the course of the breast cancer treatment.

Meg McArthur, from the Breakthrough Breast Cancer charity, told The Telegraph: "Radiotherapy is important in reducing the chance of cancer coming back but women have told Breakthrough that attending many sessions can be both physically and emotionally draining. Anything that has the potential to deliver radiotherapy treatment in a way that could benefit a patient's quality of life is to be welcomed."

Read more about this story at Breast Cancer News Today:

Latest Radiation Therapy news - http://breastcancer.einnews.com/news/radiation-therapy-breast-cancer
Latest UK Breast Cancer news - http://breastcancer.einnews.com/uk/

Located at http://breastcancer.einnews.com, Breast Cancer News Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest breast cancer news from around the world, saving them valuable time they'd spend searching for information. New users to Breast Cancer News Today can enjoy a no-obligation, one-week free trial.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.

More Than 25 pct of US Nuclear Reactors Leaking Carcinogen into Groundwater

Tue, 02 Feb 2010 15:26:36 +0000

More Than 25 pct of US Nuclear Reactors Leaking Carcinogen into Groundwater

February 2, 2010 /EIN PRESSWIRE/ The Associated Press reports that at least 27 of the 104 nuclear reactors in the US have been leaking a cancer-causing by-product of nuclear fission, with the leaks mostly occurring through deteriorating underground pipes.

The carcinogen tritium has been discovered in potentially dangerous levels (more than three times the federal safety standard) in the groundwater around the nuclear plants, most recently at the Vermont Yankee Nuclear plant.

Tritium has been linked to cancer if ingested, inhaled or absorbed through the skin in large amounts, and the concentration of tritium found in groundwater has caught the attention of the Nuclear Regulatory Commission.

Follow this story at Nuclear Power News Today:

Latest Tritium news - http://nuclearpower.einnews.com/news/radioactive-tritium
Latest Vermont Nuclear Power news - http://nuclearpower.einnews.com/vermont/

Located at http://nuclearpower.einnews.com, Nuclear Power News Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest nuclear power news from around the world, saving them valuable time they'd spend searching for information. New users to Nuclear Power News Today can enjoy a no-obligation, one-week free trial.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.

Researchers Say Coffee, Caffeine Slow Brain Cancer

Tue, 02 Feb 2010 15:25:15 +0000

Researchers Say Coffee, Caffeine Slow Brain Cancer

February 2, 2010 /EIN PRESSWIRE/ The natural amounts of caffeine found in coffee and green tea strongly suppresses the growth of brain cancer causing cells, according to South Korean researchers.

The study performed on animals showed that caffeine kept in check the growth of inositol trisphosphate receptors (IP3R) closely linked to glioblastoma, the most common and aggressive brain tumor found in humans. Researchers say that calcium plays a role in spreading the tumor cells, but caffeine counteracts that spread.

The amounts of caffeine used in the tests were equivalent to two to five cups of coffee or green tea per day.

Read more about the findings at Brain Cancer News Today:

Latest South Korea Brain Cancer news - http://braincancer.einnews.com/southkorea/
Latest Glioblastoma news - http://braincancer.einnews.com/news/glioblastoma

Located at http://braincancer.einnews.com, Brain Cancer News Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest brain cancer news from around the world, saving them valuable time they'd spend searching for information. New users to Brain Cancer News Today can enjoy a no-obligation, one-week free trial.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com.